Alphatec Holdings, Inc. (ATEC)
10.93
+0.49
(+4.69%)
USD |
NASDAQ |
Oct 15, 16:00
10.97
+0.04
(+0.37%)
After-Hours: 05:52
Alphatec Holdings Research and Development Expense (Quarterly) : 18.17M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.17M |
| March 31, 2026 | 17.56M |
| December 31, 2025 | 22.28M |
| September 30, 2025 | 18.68M |
| June 30, 2025 | 18.28M |
| March 31, 2025 | 16.58M |
| December 31, 2024 | 23.24M |
| September 30, 2024 | 20.36M |
| June 30, 2024 | 19.10M |
| March 31, 2024 | 18.01M |
| December 31, 2023 | 22.28M |
| September 30, 2023 | 20.00M |
| June 30, 2023 | 14.57M |
| March 31, 2023 | 13.26M |
| December 31, 2022 | 11.60M |
| September 30, 2022 | 12.11M |
| June 30, 2022 | 10.60M |
| March 31, 2022 | 9.722M |
| December 31, 2021 | 8.984M |
| September 30, 2021 | 9.391M |
| June 30, 2021 | 7.839M |
| March 31, 2021 | 5.801M |
| December 31, 2020 | 5.355M |
| September 30, 2020 | 4.379M |
| June 30, 2020 | 3.672M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.749M |
| December 31, 2019 | 3.436M |
| September 30, 2019 | 3.962M |
| June 30, 2019 | 3.36M |
| March 31, 2019 | 3.469M |
| December 31, 2018 | 3.032M |
| September 30, 2018 | 3.157M |
| June 30, 2018 | 2.009M |
| March 31, 2018 | 1.786M |
| December 31, 2017 | 1.437M |
| September 30, 2017 | 1.044M |
| June 30, 2017 | 0.99M |
| March 31, 2017 | 1.449M |
| December 31, 2016 | 2.449M |
| September 30, 2016 | 1.087M |
| June 30, 2016 | 2.072M |
| March 31, 2016 | 3.641M |
| December 31, 2015 | 8.106M |
| September 30, 2015 | 1.898M |
| June 30, 2015 | 3.912M |
| March 31, 2015 | 3.851M |
| December 31, 2014 | 3.661M |
| September 30, 2014 | 4.423M |
| June 30, 2014 | 4.534M |
| March 31, 2014 | 4.181M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Artivion, Inc. | 9.055M |
| Glaukos Corp. | 51.30M |
| TransMedics Group, Inc. | 31.63M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 7.979M |